Novavax (NVAX) Tops Q1 EPS by 20c, Revenues Beat

Novavax (NASDAQ: NVAX) reported Q1 EPS of ($0.58), $0.20 better than the analyst estimate of ($0.78). Revenue for the quarter came in at $3.38 million versus the consensus estimate of $1.74 million.

“Our accomplishments to-date in 2020, including significant progress in our influenza and COVID‑19 vaccine programs, are the most impressive in the company’s history,” said Stanley C. Erck, President and Chief Executive Officer of Novavax. “We shared successful pivotal Phase 3 results for NanoFlu that demonstrated both efficacy and safety in a pivotal trial, a significant milestone towards bringing this innovative product to an influenza market in need of new options. We also reacted quickly to the coronavirus pandemic by developing and quickly advancing NVX‑CoV2373, our COVID‑19 vaccine candidate, which shows strong potential to have a positive impact on this global health crisis. Looking ahead, with a strengthened balance sheet and CEPI’s substantial funding, we will focus on scaling up manufacturing and delivering clinical data for NVX‑CoV2373, while simultaneously completing the necessary actions needed to prepare our BLA filing for NanoFlu.”

For earnings history and earnings-related data on Novavax (NVAX) click here.

You May Also Be Interested In

• Keurig Dr Pepper coffee chief to depart ahead of planned split
• FTI Consulting names Jerome Nyssen senior managing director in Australia
• AeroVironment restates quarterly financials, citing $89M goodwill error